R&D News | pharmaphorum

News

LEO says chronic hand eczema drug bests its only rival

Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther

News

BenevolentAI names pharma vet Jörg Möller as its new CEO

BenevolentAI’s search for a new chief executive has concluded with the appointment of industry bigwig Dr Jörg Möller to the role, four months after Joanna Shields stepped

News

Lilly trumpets early success with deafness gene therapy

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness

News

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for

News

Trial raises hopes for simple Alzheimer’s blood test

Testing a person’s blood for a protein called phosphorylated tau could provide a means of large-scale screening for Alzheimer’s disease (AD), according to a new study.

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

LEO says chronic hand eczema drug bests its only rival

BenevolentAI names pharma vet Jörg Möller as its new CEO

Lilly trumpets early success with deafness gene therapy

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

Trial raises hopes for simple Alzheimer’s blood test

Roche ducks out of AC Immune Alzheimer's antibody alliance

Oral Wegovy bolsters Novo in Q3

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks